No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
Open Access
- 3 June 2021
- journal article
- case report
- Published by Wiley in Respirology Case Reports
- Vol. 9 (7) , e00799
Abstract
Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out.Keywords
This publication has 5 references indexed in Scilit:
- High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphomaBlood Advances, 2017
- Immune-related bone marrow failure following anti-PD1 therapyEuropean Journal of Cancer, 2017
- Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphomaAnnals of Oncology, 2017
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015